Chemotherapy-Induced Cognitive Impairment in Women With Breast Cancer: A Critique of the Literature

Jansen, Catherine E.; Miaskowski, Christine; Dodd, Marylin; Dowling, Glenna A.

doi:10.1188/05.onf.329-342

Cited by 33 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As indicated by the slopes of the lines, the speed of processing of the control group did not change much with age, but the speed of processing of the chemotherapy group worsened with increasing age. The lack of age effects in the control participants is not completely consistent with other research in the speed of processing area (Kail & Salthouse, 1994;Salthouse, 1996), and with studies of the impact of cognitive deficits on information processing (Jansen, Miaskowski, Dodd, & Dowling, 2005), all of which suggest that speed of processing decreases with age. However, none of the previous studies used the same measure of speed of processing as was used here.…”

Section: Timecontrasting

confidence: 42%

The Effects of Chemotherapy on Useful Field of View (UFOV) in Younger and Older Breast Cancer Patients

Adams-Price

Morse

Cross

et al. 2009

Experimental Aging Research

View full text Add to dashboard Cite

Chemotherapy is thought to cause cognitive deficits in some breast cancer patients, but the relative effects on older and younger breast cancer patients are unknown. The effects of chemotherapy on everyday cognitive tasks have not been examined. Thirty-eight female breast cancer survivors (3 to 45 months post chemotherapy) were compared to 55 age-matched control participants. Participants completed the Useful Field of View (UFOV), a computerized test of visual information processing that has been shown to decline with age, and which has been used to predict older adults' driving performance. Older chemotherapy patients performed more poorly than controls on the UFOV speed of processing, but not on the other two components. They also performed more poorly than younger chemotherapy patients. On the divided attention and selective attention components of the UFOV, older participants performed more poorly than younger participants, but there were no significant differences between chemotherapy patients and controls. These findings are explained in terms of brain changes thought to be caused by chemotherapy, which might have the most impact on older adults, already at risk for behavioral slowing.

show abstract

Section: Timecontrasting

confidence: 42%

The Effects of Chemotherapy on Useful Field of View (UFOV) in Younger and Older Breast Cancer Patients

Adams-Price

Morse

Cross

et al. 2009

Experimental Aging Research

View full text Add to dashboard Cite

show abstract

“…Cognitive impairment in breast cancer survivors is just beginning to be investigated in a systematic manner [50]. Two recent neuropsychological studies in breast cancer survivors reported deficits in information processing and motor function [51,52].…”

Section: Discussionmentioning

confidence: 99%

Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In retrospective and cross-sectional studies of chemotherapy-treated breast cancer survivors, compared with healthy women and patients who received only local therapy (i.e., surgery or radiation), impairment has been variably reported in speed of information processing, motor function, visual memory, language, attention and concentration, executive function, verbal memory, and visuospatial skill [70]. In a recent study with the advantage of a prospective, longitudinal design, significant cognitive decline (primarily in memory and concentration) from baseline to 18 months was measured in 18% of EBC patients treated with chemotherapy versus 11% of healthy controls [71].…”

Section: Cognitive Dysfunctionmentioning

confidence: 99%

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Cella

Fallowfield

2007

Breast Cancer Res Treat

248

240

View full text Add to dashboard Cite

In postmenopausal women with hormone receptor-positive early-stage breast cancer, the use of aromatase inhibitors (AIs) to suppress estrogen is associated with improved clinical outcomes compared with tamoxifen therapy. Women receiving such endocrine therapy may experience treatment-related side effects that negatively affect health-related quality of life (QoL) and adherence to therapy. In published clinical trials and in clinical practice, adverse events (AEs) constitute the main reason for nonadherence to endocrine treatment. Serious AEs are sometimes resolved by switching to a different agent, whereas other side effects can often be managed to allow patients to remain on therapy without sacrificing QoL. Across all adjuvant endocrine trials, regardless of the treatment received, vasomotor symptoms such as hot flashes are the most common side effects. Other frequently reported side effects, such as vaginal discharge, vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant endocrine therapy, focusing on those that are amenable to pharmacologic or nonpharmacologic management without treatment discontinuation. Also highlighted are specific management strategies that may improve patient QoL and thereby optimize adherence to therapy, which in turn might improve patient outcomes.

show abstract

Chemotherapy-Induced Cognitive Impairment in Women With Breast Cancer: A Critique of the Literature

Abstract: The potential for chemotherapy-induced impairments in cognitive function may influence patients' ability to give informed consent, identify treatment toxicities, learn self-care measures, and perform self-care behaviors.

Cited by 33 publications

References 35 publications

The Effects of Chemotherapy on Useful Field of View (UFOV) in Younger and Older Breast Cancer Patients

The Effects of Chemotherapy on Useful Field of View (UFOV) in Younger and Older Breast Cancer Patients

Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report

Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy

Contact Info

Product

Resources

About